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Introduction {#sec005}
============

Over the last decades, *Clostridium*. *difficile* infection (CDI) has emerged as a leading cause of nosocomial diarrhea, accounting for 15% to 25% of antibiotic-associated diarrhea \[[@pone.0185891.ref001]\]. CDI is a life-threatening and costly disease, associated with a one-month mortality ranging from 3 to 30% \[[@pone.0185891.ref002]\] and more than \$1.5 billion in costs a year in the United States \[[@pone.0185891.ref003]\]. The main virulence factors of *C*. *difficile* are toxins A and B, which are respectively encoded by the *tcdA* and *tcdB* genes, with expression of either toxin sufficient to cause disease \[[@pone.0185891.ref004]\]. Furthermore, approximately 6 to 12.5% toxigenic strains also produce a third toxin known as binary toxin, encoded by the *cdt* locus \[[@pone.0185891.ref005]\]. Although its role in CDI pathogenesis has been unclear, the presence of binary toxin in combination with a single-nucleotide deletion at base pair 117 within the negative toxin regulator gene *tcdC* is considered a hallmark for 'hypervirulent' 027/NAP1/BI (PCR-ribotype 027 or NAP1 according to pulse-field gel electrophoresis typing, or BI according to restriction enzyme analysis typing) strains which have caused several important outbreaks of severe CDIs \[[@pone.0185891.ref006]\]. These strains have been shown to produce a large amount of toxins *in vitro* and are associated with erythromycin and newer fluoroquinolones resistance.

The diagnosis of CDI is usually made based on the combination of clinical presentation and laboratory tests. Despite numerous laboratory methods are now available, the diagnosis of CDI still remains a challenge. The anaerobic toxigenic culture (TC) and culture cytotoxicity neutralization assay (CCNA) were often used as the laboratory reference tests for detecting *C*. *difficile*. However, the two tests have limitations such as a long turnaround time (48--72 hours) and technical complexities \[[@pone.0185891.ref007]\], which may result in delayed proper treatment. In practice, enzyme immunoassays (EIAs) for detecting *C*. *difficile* toxins have been the most frequently employed tests in clinical labs. There are a number of commercially available EIAs for *C*. *difficile* toxins, which are used conveniently and provide a quick result for a low cost with good specificity. However, it was ultimately demonstrated that EIAs cannot be used as standalone tests due to its low sensitivity \[[@pone.0185891.ref008]\]. Therefore, accurate and rapid diagnosis of CDI is essential for proper treatment and infection control.

The technological advancement of molecular biotechnologies has been of interest for detecting CDI. Recently, Nucleic acid amplification tests (NAATs) for the direct detection of toxigenic *C*. *difficile* have been developed and implemented in many labs due to its high sensitivity as good as TC. Currently, several NAATs have been cleared by Food and Drug Administration (FDA) \[[@pone.0185891.ref009]\] and supported by recent guidelines by the American Society of Microbiology \[[@pone.0185891.ref010]\]. Most commercially available NAATs target the *tcdB* gene, which is produced by all the toxigenic strains of *C*. *difficile* \[[@pone.0185891.ref011]\]. The Xpert CD assay (Cepheid, Sunnyvale, CA, USA) is a multiplex PCR assay. As described in detail previously by Burnham, C. A. D et al \[[@pone.0185891.ref009]\], the unique features of this assay are that it not only detects *tcdB* but also the binary toxin genes and the deletion at nucleotide 117 on *tcdC* (Δ117) as hallmarkers for presumptive identification of 'hypervirulent' 027/NAP1/BI strains. This assay is among the simplest to perform and is also the most rapid of the available NAATs that the turn-around time is about 1 hour.

According to the Society for Healthcare Epidemiology of America and the Infectious Diseases Society of America guidelines, "...PCR testing appears to be rapid, sensitive, and specific and may ultimately address testing concerns. More data on utility are necessary before this methodology can be recommended for routine testing". Several previous studies have examined the performance of the Xpert CD assay for detecting CDI, however, the sensitivity and specificity results have been inconsistent. In the present study, a new meta-analysis was performed to comprehensively evaluate the overall diagnostic accuracy of the Xpert CD assay in detecting CDI compared with reference tests.

Methods {#sec006}
=======

We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines in our study.

Literature search {#sec007}
-----------------

Original articles published in English up to the end of July 2017 were searched in PubMed, EMBASE and Cochrane Library databases by two investigators (Y. Bai and J. Li). The search terms used were as follows: *Clostridium difficile* AND (Xpert *C*. *difficile* OR molecular diagnostic techniques). Reference lists from included studies were also searched.

Study criteria {#sec008}
--------------

We systematically searched the literature using the following predetermined inclusion criteria. Studies evaluating Xpert CD as a diagnostic test for CDI were eligible for inclusion if the studies 1) described original research; 2) performed stool samples analyses from human patients, either children or adults; 3) compared Xpert CD to a reference method--either CCNA or anaerobic TC; 4) had extractable data to fill the 4 cells of a 2 × 2 table for diagnostic tests (true positives (TP), true negatives (TN), false positives (FP), and false negatives (FN)).

Relevant publications were excluded if they were duplicated articles, letters without original data, animal studies, case reports, editorials, and reviews. Studies with fewer than 20 samples were also excluded to reduce selection bias. Articles that contain data from infants were excluded because infants rarely develop clinical infection.

Data extraction {#sec009}
---------------

Two investigators (Y. Bai and J. Li) extracted data from full text of the included studies independently. Disagreements were resolved by consensus. Information was extracted on the first author, publication year, country where the study was conducted, sample size, reference tests the diagnosis used, the number of TP, the number of FP, the number of FN, and the number of TN. These were summarized as sensitivity, TP/(TP+FN); specificity, TN/(TN + FP);and prevalence, (TP+FN)/(TP+FN+TN+FN).

Quality of study reports {#sec010}
------------------------

We applied the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) to assess the quality of included studies (<http://www.bris.ac.uk/quadas/>), an updated version of the original software \[[@pone.0185891.ref012]\]. QUADAS-2 is used in systematic reviews to evaluate the risk of bias and applicability of diagnostic accuracy studies, and consists of four key domains: patient selection, index test, reference standard, and flow and timing. Each domain is assessed for risk of bias and the first three are also evaluated for applicability. Signaling questions were included to assist in judgments about the risk of bias \[[@pone.0185891.ref013]\]. If the answers to all signaling questions for a domain were "yes," the risk of bias is judged as "low;" if any signaling question in a domain was "no," risk of bias is judged as "high." The unclear bias should only be used if insufficient information was supplied \[[@pone.0185891.ref013]\]. Applicability was judged as low, high, or unclear with the similar criteria.

Statistical analysis {#sec011}
--------------------

### Accuracy estimates {#sec012}

Meta-analyses were performed using two software programs: STATA 13.0 (Stata Corporation, Texas, USA) and Cochrane RevMan 5.2. Sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR), forest plots and summary receiver operating characteristic (SROC) curves were analyzed with the 'midas' module for STATA 13.0, based on the random model effect. Quality of studies was assessed with RevMan 5.2.

### Heterogeneity {#sec013}

We used chi-square test and *I*^*2*^ (*p* \< 0.05 and *I*^*2*^ \> 50% indicated significant heterogeneity) to identify heterogeneity. The methods to evaluate the heterogeneity were described detailedly in our previous published study \[[@pone.0185891.ref014]\]. The further reasons for heterogeneity of the data were addressed by performing subgroup analyses on prespecified variable: the calculated prevalence of *C*. *difficile* (\<15% and ≥15%) and the sample size (\< median size 246 and ≥246).

### Fagan\'s nomogram {#sec014}

The method to depict visual Fagan\'s nomogram was described in detail as previously \[[@pone.0185891.ref015]\].

Results {#sec015}
=======

Characteristics of selected studies {#sec016}
-----------------------------------

A flow chart of the study selection process is shown in [Fig 1](#pone.0185891.g001){ref-type="fig"}. A total of 193 potentially relevant citations were identified from all searches. Finally, according to the inclusion and exclusion criteria, 20 eligible articles fulfilled the inclusion criteria and were included in the meta-analysis. Because diagnostic tests performed with different reference methods occurred in the same article, 22 independent studies (including 9352 samples) were defined in the meta-analysis. [Table 1](#pone.0185891.t001){ref-type="table"} shows the characteristics of these included studies \[[@pone.0185891.ref016]--[@pone.0185891.ref035]\]. The prevalence of CDI across all studies ranged from 10% to 47.9%. Two studies used CCNA as a reference test \[[@pone.0185891.ref016],[@pone.0185891.ref019]\].In one study, the investigators reported the diagnostic accuracy separately for both the reference standards \[[@pone.0185891.ref019]\]. In another study, the investigators reported the diagnostic accuracy separately for TC and Enriched TC \[[@pone.0185891.ref017]\]. Most of the studies were prospective in design.

![Flow chart of study selection.](pone.0185891.g001){#pone.0185891.g001}
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###### Summary of the included studies.

![](pone.0185891.t001){#pone.0185891.t001g}

  First author                              Year   Country        Sample size   Reference test                                TP [^1)^](#t001fn001){ref-type="table-fn"}   FP[^2)^](#t001fn002){ref-type="table-fn"}   FN[^3)^](#t001fn003){ref-type="table-fn"}   TN[^4)^](#t001fn004){ref-type="table-fn"}   Calculated prevalence(%)
  ----------------------------------------- ------ -------------- ------------- --------------------------------------------- -------------------------------------------- ------------------------------------------- ------------------------------------------- ------------------------------------------- --------------------------
  Huang \[[@pone.0185891.ref016]\]          2009   USA            220           CCNA[^5)^](#t001fn005){ref-type="table-fn"}   34                                           13                                          1                                           172                                         15.9
  Tenover-1\[[@pone.0185891.ref017]\]       2010   Canada & USA   2296          TC[^6)^](#t001fn006){ref-type="table-fn"}     245                                          188                                         3                                           1860                                        10.8
  Tenover-2\[[@pone.0185891.ref017]\]       2010   Canada & USA   2296          Enriched TC                                   316                                          117                                         22                                          1841                                        14.7
  Novak-Weekley\[[@pone.0185891.ref018]\]   2010   USA            428           Enriched TC                                   68                                           13                                          4                                           343                                         16.8
  Swindells-1\[[@pone.0185891.ref019]\]     2010   UK             150           CCNA                                          15                                           4                                           0                                           131                                         10
  Swindells-2\[[@pone.0185891.ref019]\]     2010   UK             150           TC                                            19                                           1                                           0                                           130                                         12.7
  Goldenberg\[[@pone.0185891.ref020]\]      2010   UK             224           TC                                            57                                           6                                           0                                           161                                         25.4
  Dubberke \[[@pone.0185891.ref021]\]       2011   USA            150           TC                                            44                                           7                                           0                                           99                                          29.3
  Zidaric \[[@pone.0185891.ref022]\]        2011   Slovenia       178           TC                                            27                                           4                                           1                                           146                                         15.7
  Buchan \[[@pone.0185891.ref023]\]         2012   USA            275           TC                                            58                                           18                                          0                                           199                                         21.1
  Viala \[[@pone.0185891.ref024]\]          2012   France         94            TC                                            44                                           1                                           1                                           48                                          47.9
  Shin \[[@pone.0185891.ref025]\]           2012   Korea          248           TC                                            49                                           10                                          0                                           189                                         19.6
  Dalpke \[[@pone.0185891.ref026]\]         2013   Germany        448           TC                                            72                                           8                                           2                                           366                                         16.5
  Eigner \[[@pone.0185891.ref027]\]         2014   Germany        245           TC                                            74                                           8                                           2                                           161                                         31
  Gilbreath \[[@pone.0185891.ref028]\]      2014   USA            190           TC                                            23                                           2                                           0                                           165                                         12.1
  Jensen \[[@pone.0185891.ref029]\]         2015   Denmark        299           TC                                            38                                           20                                          0                                           241                                         16.6
  Jazmati \[[@pone.0185891.ref030]\]        2015   Germany        199           Enriched TC                                   28                                           17                                          0                                           154                                         14.1
  Yoo \[[@pone.0185891.ref031]\]            2015   Korea          254           TC                                            72                                           2                                           15                                          165                                         34.1
  Moon \[[@pone.0185891.ref032]\]           2016   Korea          258           TC                                            52                                           11                                          3                                           192                                         21.3
  Moon \[[@pone.0185891.ref033]\]           2016   Korea          270           TC                                            52                                           11                                          3                                           204                                         20.4
  Shin \[[@pone.0185891.ref034]\]           2016   Korea          339           TC                                            78                                           18                                          9                                           234                                         25.7
  Rajabally \[[@pone.0185891.ref035]\]      2016   South Africa   141           TC                                            27                                           3                                           3                                           108                                         21.3

^1)^*TP*:true positives

^2)^*FP*:false positives

^3)^*FN*:false negatives

^4)^*TN*: true negatives

^5)^*CCNA*: culture cytotoxicity neutralization assay

^6)^*TC*: toxigenic culture

Quality assessment {#sec017}
------------------

A quality assessment of all of the included articles is illustrated in [Fig 2](#pone.0185891.g002){ref-type="fig"}. In conclusion, patient selection was the most high-risk or unclear risk bias and high risk applicability concerns. More than half of the included articles were at either high risk or unclear risk bias in "patient selection" and "flow and timing" domains of QUARDAS-2 due to lack of detail regarding timing, inconsecutive, or nonrandom patient selection and blinding. A total of 9 (45%) articles were at low risk, 7 articles (35%) were of unclear risk, and 4 articles (20%) were at high risk for patient selection bias. A total of 12 articles (60%) were at high risk for flow and timing bias, because of the fact that not all selected patients were included in the diagnostic analysis. Most of the articles were at either low or unclear risk for index test and reference standard bias. Regarding applicability, half of the articles were at high risk for patient selection; however, all selected articles (n = 20, 100%) were at low risk of index test and the reference standard. In conclusion, patient selection was the most high-risk or unclear risk bias and high risk applicability concerns.

![Quality assessment of included studies.](pone.0185891.g002){#pone.0185891.g002}

Diagnostic accuracy {#sec018}
-------------------

Results are given as values (95% CI). Using a random-effects model, the results were as follows: sensitivity 0.97(0.95--0.99), *I*^*2*^ = 76.4%; specificity 0.95(0.94--0.96), *I*^*2*^ = 85.4% ([Fig 3](#pone.0185891.g003){ref-type="fig"}); PLR 21.41(16.66--27.52), *I*^*2*^ = 78.9%; NLR 0.03 (0.02--0.05), *I*^*2*^ = 72.55%; DOR 762.13(401.82--1445.52), *I*^*2*^ = 100%; and AUC 0.99 (0.97--0.99) ([Fig 3](#pone.0185891.g003){ref-type="fig"}). The results indicated a good level of overall accuracy.

![Forest plots of the pooled sensitivity and specificity and SROC curve of Xpert CD for detection of CDI.\
(a) Forest plots of the pooled sensitivity and specificity. Each solid square represents an individual study. Error bars represent 95% CI. Diamond indicates the pooled sensitivity and specificity for all of the studies. (b). SROC curve.](pone.0185891.g003){#pone.0185891.g003}

The relationship between pretest probability and posttest probability was depicted by visual Fagan\'s nomogram. For patients with a pretest probability of 20%, the posttest probability of positive results was 84%, and posttest probability of negative results was 1% ([Fig 4](#pone.0185891.g004){ref-type="fig"}).

![Fagan nomogram of Xpert CD assay for diagnosis of CDI.](pone.0185891.g004){#pone.0185891.g004}

### Heterogeneity {#sec019}

There was substantial heterogeneity for all the statistical measures. The heterogeneity test results of sensitivity and specificity are illustrated in the forest plots ([Fig 3](#pone.0185891.g003){ref-type="fig"}).The Spearman correlation coefficient between the logit of sensitivity and logit of 1-specificity was used to assess the threshold/cut-off effect. The Spearman correlation coefficient (*p* value) in diagnostic of CDI was 0.270 (*p* = 0.201). This indicated that the heterogeneity might not be due to threshold/cut-off effect. To assess for causes of variations other than threshold, we performed subgroup analyses in terms of CDI prevalence and sample size.

### Subgroup analyses {#sec020}

At a prevalence of \<15% (6 studies, 5281samples), the sensitivity was 0.99 (0.89--1.00), *I*^*2*^ = 86.4%; specificity, 0.96 (0.92--0.98), *I*^*2*^ = 97.5%; PLR 25.07 (11.68--53.79), *I*^*2*^ = 96.4%; NLR 0.03 (0.02--0.05), *I*^*2*^ = 85.25%; DOR 2672.14 (141.68--50398.07), *I*^*2*^ = 100%; and AUC 0.99 (0.97--0.99).

At a prevalence of \>15% (16 studies, 4071samples), the sensitivity was 0.97 (0.94--0.99), *I*^*2*^ = 71.56%; specificity, 0.95 (0.94--0.96), *I*^*2*^ = 54.45%; PLR 21.22 (16.73--26.91), *I*^*2*^ = 25.39%; NLR 0.03 (0.02--0.06), *I*^*2*^ = 66.83%; DOR 681.72 (344.60--1348.67), *I*^*2*^ = 99.82%; and AUC 0.98 (0.97--0.99).

The median sample size was 246. In studies with a sample size \<246 (11 studies, 1941 samples), the sensitivity was 0.98 (0.95--0.99), *I*^*2*^ = 39.1%; specificity 0.96 (0.94--0.98), *I*^*2*^ = 70.52%; PLR 27.05 (17.65--41.46), *I*^*2*^ = 51.46%; NLR 0.02 (0.01--0.05), *I*^*2*^ = 15.31%; DOR 1420.95 (495.97--4071.02), *I*^*2*^ = 73.31%; and AUC 1.00 (0.98--1.00).

In studies with a sample size \>246 (11 studies, 7411 samples), the sensitivity was 0.96(0.93--0.98), *I*^*2*^ = 81.25%; specificity 0.95 (0.95--0.96), *I*^*2*^ = 84.85%; PLR 18.21 (13.81--24.01), *I*^*2*^ = 72.93%; NLR 0.04 (0.02--0.08), *I*^*2*^ = 78.42%; DOR 454.58 (239.02--864.57), *I*^*2*^ = 98.09%; and AUC 0.98(0.97--0.99).

The theoretical values of PPV and NPV were calculated using the pooled sensitivity (0.97) and specificity (0.95) values and plotted against increasing CDI prevalence. The PPV performance is variable and correlated positively with increasing CDI prevalence, whereas NPV remained almost quite high ([Fig 5](#pone.0185891.g005){ref-type="fig"}).

![Theoretical values of PPV and NPV for increasing CDI prevalence calculated using pooled sensitivity (97%) and specificity (95%).](pone.0185891.g005){#pone.0185891.g005}

Discussion {#sec021}
==========

In recent years, NAATs for the direct detection of *C*. *difficile* toxin genes in stool samples have garnered strong research interest worldwide and are a highly sensitive alternative to the EIAs, the time-consuming TC and CCNA. To that end, we focused on the Xpert CD assay which has been cleared by FDA to rapidly diagnose patients with CDI. The Xpert CD assay is now implemented in many countries due to its shorter turnaround time, thus a more effective procedure. The most significant advantage of the Xpert CD assay is its rapidity and simplicity. As described previously \[[@pone.0185891.ref009],[@pone.0185891.ref028]\], besides detecting toxigenic *C*. *difficile*, the Xpert CD assay reports presumptive identification of 'hypervirulent' 027/NAP1/BI (positive for *cdt* and *tcdC* Δ117). The 14-day mortality was very high for 027 /NAP1/BI (20%), compared to an overall mortality of 13% (p \< 0.0001) \[[@pone.0185891.ref036]\]. A previously published study reported that the agreement between the Xpert CD assay and PCR-ribotyping was 93% \[[@pone.0185891.ref037]\]. And another study found "very good" agreement at 97.9% between this assay and multilocus sequence typing (MLST) for identification of *C*. *difficile* NAP1 \[[@pone.0185891.ref038]\]. Recently, studies focusing on the diagnostic accuracy of the Xpert CD assay were conducted in many settings, but with inconsistent results. To provide much more evidence-based results for utility of this assay in routine testing, we conducted this meta-analysis to evaluate the diagnostic accuracy of the Xpert CD assay for direct detection of CDI compared with conventional reference tests.

In the literature there are two meta-analyses in which the Xpert CD assay has been assessed \[[@pone.0185891.ref039],[@pone.0185891.ref040]\]. The first analysis, performed in 2012, was limited by only including four studies that could not fully assess the clinical application of this assay \[[@pone.0185891.ref039]\]. The second analysis, as a part of a review published in 2013, focused on three popular commercial NAATs, including the Xpert CD assay, only evaluated the assay compared to TC and only reported pooled sensitivity \[[@pone.0185891.ref040]\]. As we know, to evaluate the diagnostic accuracy of this assay, other measures such as specificity, DOR, PLR and NLR also should be reported. Our meta-analysis identified several additional studies since the publication of the two reviews. To the best of our knowledge, the present meta-analysis, with 22 studies included, is the first study that has comprehensively evaluated the overall diagnostic accuracy of the Xpert CD assay in detecting toxigenic CDI. In our meta-analysis, the Xpert CD assay showed high pooled sensitivity (97%) and specificity (95%) for detection of CDI, with lower specificity than sensitivity which was one of the common characteristics of NAATs. While NAATs have highly sensitivity, there are some important issues that have been raised regarding their practical application. The main issue regarding the clinical utility of NAATs, especially the PPV and specificity, is linked to the detection of genes versus actual toxins. Someone concerned that NAATs can be positive in both disease states and colonization \[[@pone.0185891.ref009]\]. Detection of toxin genes does not necessarily correlate with expression of toxin, nor disease. Another limitation of the NAATs is that nearly all assays focus on *tcdB* detection, but if a strain did not produce toxin B or was *tcdB*-variant, it would led to a false-negative result. Some researches have reported that inappropriate test ordering can also impact the clinical specificity of tests \[[@pone.0185891.ref021]\].

Given a pretest probability of 20%, the posttest probability for a positive test results was 84%, and posttest probability of negative test result was 1%. The PPV performance correlated positively with increasing CDI prevalence.This meta-analysis showed that Xpert CD assay had high mean DOR and large AUC values, indicating a high value of overall accuracy for the detection of CDI. A quite high PLR and a very low NLR for the detection CDI in our study indicated an excellent ability to both confirm and exclude CDI. The better diagnostic accuracy found in our study may provide more powerful evidence for routine clinical application of Xpert CD assay.

We found significant heterogeneity for diagnostic parameters among the studies analyzed. The Spearman correlation coefficient between the logit of sensitivity and logit of 1-specificity was not significant, indicating that the heterogeneity was not caused by threshold/cut-off effect. Thus, subgroup analyses based on CDI prevalence and sample size were performed to test for causes of variations other than threshold effect. There were no significant heterogeneity for PLR (*I*^*2*^ = 25.39%, *p* = 0.01) when CDI prevalence of studies greater than 15% were pooled and that for sensitivity (*I*^*2*^ = 39.1%, *p* = 0.09) and NLR (*I*^*2*^ = 15.31%, *p* = 0.30) when sample size of studies less than median sample size were pooled. The results suggested that the CDI prevalence and sample size could partly explain the heterogeneity. Even so, the considerable heterogeneity in the results remained unexplained, which may be caused by the various baseline criteria for accepting stool samples for testing.

Our meta-analysis had several methodological strengths, such as standard protocol and rigorous statistical methods. However, our meta-analysis also had several limitations. First, the studies included in this analysis have various baseline criteria for accepting stool samples, different patient populations and institutional characteristics. Most studies did not specify the exact criteria used to submit patient stool samples to the laboratory for testing, which made it difficult to avoid detecting asymptomatic carriers. Second, the present authors only included studies published in English, and some studies missing data to calculate sensitivity and specificity were excluded since the authors could not be contacted. Moreover, we did not show the detailed data about analyzing studies that used TC or CCNA or enriched TC as the reference standard separately, because of only 2 studies used CCNA and 3 studies used enriched TC as reference tests. It did not reduce potential heterogeneity when studies with TC as reference method were pooled (data not shown).

In general, although the Xpert CD assay showed good accuracy for CDI detection in this meta-analysis, some important issues remain to be addressed. Like the problems about NAATs we mentioned above, one of the more important questions concern the clinical utility of this assay is that it specifically detects the *tcdB* gene encoding the toxin and not an actual toxin. Therefore, asymptomatic carriers can be misdiagnosed as disease state if inappropriate testing is performed. The asymptomatic colonization rate is about 2% in healthy adults and can be as high as 51% for residents of long term care facilities \[[@pone.0185891.ref041]\]. To avoid over diagnosis and overtreatment of toxigenic CDI by using the Xpert CD assay, it must be strictly limited to diarrheal stool specimen in patients without laxatives. The clinician should be mindful of the limits of this rapid molecular assay and clinical assessment is necessary to detect true infection. Also, the assay can remain positive for weeks after the resolution of clinical symptoms and should not be repeated for monitoring treatment.

Another important issue of cost-effectiveness of the molecular methods, including the Xpert CD assay, has been raised by laboratorians and administrators. The molecular assays cost up to 2- to 3-fold more than EIAs. To lessen the cost of NAATs, a two-step algorithm based on glutamate dehydrogenase (GDH) detection and NAAT in case of a positive result constitute an excellent alternative to the exclusive use of NAATs. Culbreath *et al*. reported that this algorithm was 56% cheaper than applying the Xpert CD systematically in their institution (US\$70,633 *vs*. US\$159,877 per 1000 tests) \[[@pone.0185891.ref042]\]. Given the rapidity and simplicity of the Xpert CD assay that are helpful for timely implementation of appropriate therapy and contact precaution, this two-step algorithms may not offer an advantage but may be used for cost savings. On the other hand, the higher cost of NAATs may be counterbalanced by a decrease in healthcare-associated infections costs. Babady *et al*. reported that performing the Xpert CD test alone was less expensive than two-step algorithms when labor costs (accessioning, test performance, and reporting of results) were considered \[[@pone.0185891.ref043]\]. In the future, it is needed to assess the overall cost-effectiveness of Xpert CD for the diagnosis of *C*. *difficile* disease, including comprehensive laboratory costs and overall hospital costs.

In conclusion, the present meta-analysis showed that the Xpert CD assay had good accuracy for detecting CDI, suggesting that it has good utility as a rapid screening molecular tool. In the future, studies are needed to focus on the prediction of the disease severity. While several biomarkers that correlates with active CDI have been evaluated (such as fecal lactoferrin, calprotectin, interleukin-8), combining the Xpert CD assay with biomarkers to diagnosis active CDI will likely be an area of investigation in the coming years. This assay will probably be considered as one of the standard diagnostic tests for CDI, either as a standalone test or included in a multistep algorithm.
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